PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Biogen Idec and PDL: Licensing Triumphs over Acquisition
From issue 63 of the PharmaDeals Review (2005-09-01)
Biogen Idec's and Protein Design Labs' recent antibody licensing arrangement has helped to dispel trepidation that mergers and acquisitions are replacing licensing agreements. In this feature, we look at why the deal was positive for PDL in the context of its planned business strategy.
Available as PDF
(Subscribers only)
Baltic States Bring Biotech Expertise to Enlarged Europe
From issue 63 of the PharmaDeals Review (2005-09-01)
Estonia, Latvia and Lithuania joined the EU in 2004, but since 2001 there has been rapid development in their biotech sectors, although these are still small. Factors contributing to this growth are discussed, and the focus and characteristics of the biotech sectors in each country are outlined, using selected companies as examples.
Available as PDF
(Subscribers only)
Therapy Focus: Rheumatoid Arthritis
From issue 63 of the PharmaDeals Review (2005-09-01)
Rheumatoid arthritis is a common chronic disease, and healthcare companies are increasingly eager to develop agents with the potential to treat the causes of the condition. As discussed in this feature, the considerable level of innovation and inter-company collaboration this requires is evident from an overview of recent rheumatoid arthritis deals.
Available as PDF
(Subscribers only)
Alkermes, Cephalon and Vivitrex®: Pioneering the Alcohol Dependence Market
From issue 62 of the PharmaDeals Review (2005-08-01)
Alkermes has chosen Cephalon as the US partner for Vivitrex®, its sustained-release version of naltrexone that it awaiting approval by the US FDA for the treatment of alcohol dependence. The deal is notable for a number of reasons, not least the size of the guaranteed payments and the way in which responsibilities, costs and profits will be shared by the two parties.
Available as PDF
(Subscribers only)
Pfizer and Vicuron: A Taste of Things to Come?
From issue 62 of the PharmaDeals Review (2005-08-01)
The announcement by Pfizer that it is to acquire anti-infectives specialist Vicuron generated a certain amount of excitement across the industry. This article examines the various factors behind the deal, and demonstrates that one might expect an increasing number of such acquisitions to take place in the coming months.
Last Issue PDF
RSS